Cargando…

EMEA and Gene Therapy Medicinal Products Development in the European Union

The evaluation of quality, safety, and efficacy of medicinal products by the European Medicines Evaluation Agency (EMEA) via the centralized procedure is the only available regulatory procedure for obtaining marketing authorization for gene therapy (GT) medicinal products in the European Union. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papaluca Amati, Marisa, Pignatti, Francesco, Nolte, Alexis, Amerasinghe, Nirosha, Gustafsson, Daniel, Moulon, Isabelle, Le Courtois, Patrick
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2003
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC179762/ https://www.ncbi.nlm.nih.gov/pubmed/12686717 http://dx.doi.org/10.1155/S1110724303209104

Ejemplares similares

Psychopharmacology at the era of EMEA (European Medicines Agency)
por: Pestana, Luis Camara, et al.
Publicado: (2010)

The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials
por: Marchetti, S, et al.
Publicado: (2007)

Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency
por: Elsäßer, Amelie, et al.
Publicado: (2014)

Anne Richards, Chief Investment Officer, Head of EMEA - CERN & Society Board Meeting
por: Brice, Maximilien
Publicado: (2014)

Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency
por: Collignon, Olivier, et al.
Publicado: (2018)

Affordability of medicines in the European Union
por: Zaprutko, Tomasz, et al.
Publicado: (2017)

European Union ban on Ayurvedic Medicines
por: Patwardhan, Bhushan
Publicado: (2011)

Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders
por: Mulder, Jorn, et al.
Publicado: (2021)

Valorising and Creating Access to Innovative Medicines in the European Union
por: Annemans, Lieven, et al.
Publicado: (2011)

An overview of Personalized Medicine landscape and policies in the European Union
por: Beccia, F, et al.
Publicado: (2022)

Austerity and Abortion in the European Union
por: Lima, Joana Madureira, et al.
Publicado: (2016)

Optimizing Pediatric Medicine Developments in the European Union Through Pragmatic Approaches
por: Rei Bolislis, Winona, et al.
Publicado: (2021)

Cell-based medicinal products approved in the European Union: current evidence and perspectives
por: Bellino, Stefania, et al.
Publicado: (2023)

Scanning the horizon: a systematic literature review of methodologies
por: Hines, Philip, et al.
Publicado: (2019)

Use of biomarkers in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2014)

Improving the Safety of Medicines in the European Union: From Signals to Action
por: Potts, Joanne, et al.
Publicado: (2019)

The challenges of access to innovative medicines with limited evidence in the European Union
por: Vallano, Antonio, et al.
Publicado: (2023)

The European Health Union and the protection of public health in the European Union: Is the European Union prepared for future cross-border health threats?
por: Seitz, Claudia
Publicado: (2023)

Mapping the teaching of honeybee veterinary medicine in the European Union and European Free Trade Area
por: Iatridou, Despoina, et al.
Publicado: (2019)

The European Union and the Regions /
Publicado: (1995)

Regulatory Science and Innovation Programme for Europe (ReScIPE): A proposed model
por: Hines, Philip A., et al.
Publicado: (2019)

Establishing medical plausibility in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2014)

A Regulatory Take on Cannabis and Cannabinoids for Medicinal use in the European Union
por: Lipnik-Štangelj, Metoda, et al.
Publicado: (2020)

A survey of experts on personalized medicine landscape in European Union and China
por: Hoxhaj, Ilda, et al.
Publicado: (2023)

Precision Medicine in Non-Communicable Diseases
por: Novelli, Giuseppe, et al.
Publicado: (2020)

Mapping the teaching of aquatic animal veterinary medicine in the European Union and European Free Trade Area
por: Iatridou, Despoina, et al.
Publicado: (2018)

Does the development of new medicinal products in the European Union address global and regional health concerns?
por: Catalá-López,, Ferrán, et al.
Publicado: (2010)

Unproven cell interventions in Poland and the exploitation of European Union law on advanced therapy medicinal products
por: Dulak, Józef, et al.
Publicado: (2023)

Report on the state of the European Union /
Publicado: (2005)

The government and politics of the European Union /
por: Nugent, Neill
Publicado: (1994)

Bluetongue Epidemiology in the European Union
por: Saegerman, Claude, et al.
Publicado: (2008)

Policy-making in the European Union
por: Wallace, Helen, et al.
Publicado: (2015)

European Union Retreat at CERN
por: Ordan, Julien
Publicado: (2019)

The political economy of the European Union
por: Dür, Andreas, et al.
Publicado: (2020)

Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma
por: Postmus, Douwe, et al.
Publicado: (2017)

The European Health Union: European Union’s Concern about Health for All. Concepts, Definition, and Scenarios
por: Nabbe, Marie, et al.
Publicado: (2021)

Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2015)

Production losses attributable to suicide deaths in European Union
por: Łyszczarz, Błażej
Publicado: (2021)

A review of product safety regulations in the European Union
por: Ruohonen, Jukka
Publicado: (2022)

Federalism and European union : the building of Europe, 1950-2000 /
por: Burgess, Michael, 1949-
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_gbqmfhol49f1295rik0mcupqur